Showing 741-753 of 753 for: Cochrane Systematic Reviews > Pharmacotherapeutics 
- Vitamin E for neuroleptic-induced tardive dyskinesia
Cochrane Systematic Reviews, 4-Oct-2011
Antipsychotic (neuroleptic) medication is used extensively to treat people with chronic mental illnesses. Its use, however, is associated with adverse effects, including movement disorders such as tardive dyskinesia (TD) – a problem often seen as repetiti
- Vitamin E supplementation for prevention of morbidity and mortality in preterm infants
Cochrane Systematic Reviews, 12-Aug-2008
Treating very low birth weight (VLBW) infants with pharmacologic doses of vitamin E as an antioxidant agent has been proposed for preventing or limiting retinopathy of prematurity, intracranial hemorrhage, hemolytic anemia, and chronic lung disease. Howev
- Vitamin E supplementation in pregnancy
Cochrane Systematic Reviews, 22-Mar-2016
Vitamin E supplementation may help reduce the risk of pregnancy complications involving oxidative stress, such as pre-eclampsia. There is a need to evaluate the efficacy and safety of vitamin E supplementation in pregnancy.
- Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin
Cochrane Systematic Reviews, 14-Jan-2013
People who have had a transient ischaemic attack (TIA) or non-disabling ischaemic stroke have an annual risk of major vascular events of between 4% and 11%. Aspirin reduces this risk by 20% at most. Secondary prevention trials after myocardial infarction
- Vitamin supplementation for preventing miscarriage
Cochrane Systematic Reviews, 7-Dec-2010
Miscarriage is a common complication of pregnancy that can be caused by a wide range of factors. Poor dietary intake of vitamins has been associated with an increased risk of miscarriage, therefore supplementing women with vitamins either prior to or in e
- Vitamins for epilepsy
Cochrane Systematic Reviews, 10-Aug-2009
Vitamins have been reported to be effective in controlling certain types of seizures and to prevent some of the harmful effects of antiepileptic drugs (AEDs). In this review we will summarize evidence from randomized controlled trials.
- Written information about individual medicines for consumers
Cochrane Systematic Reviews, 14-Sep-2011
Medicines are the most common intervention in most health services. As with all treatments, those taking medicines need sufficient information: to enable them to take and use the medicines effectively, to understand the potential harms and benefits, and t
- Ziprasidone for schizophrenia and severe mental illness
Cochrane Systematic Reviews, 18-Jan-2012
Typical antipsychotic drugs are widely used as the first line treatment for people with schizophrenia. However, the atypical class of antipsychotic drugs are making important inroads into this approach. Atypical is a widely used term used to describe some
- Ziprasidone versus other atypical antipsychotics for schizophrenia
Cochrane Systematic Reviews, 12-Mar-2013
In many countries of the industrialised world second generation ('atypical') antipsychotics have become the first line drug treatment for people with schizophrenia. The question as to whether, and if so how much, the effects of the various new generation
- Zotepine for schizophrenia
Cochrane Systematic Reviews, 18-Jan-2012
Zotepine is a relatively new antipsychotic often used for the treatment of people with schizophrenia. It is claimed to be particularly effective for negative symptoms.
- Zotepine versus other atypical antipsychotics for schizophrenia
Cochrane Systematic Reviews, 7-Dec-2011
In many parts of the world, particularly in industrialised countries, second generation (atypical) antipsychotic drugs have become first line treatment for people suffering from schizophrenia. The question as to whether the effects of various second gener
- Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses
Cochrane Systematic Reviews, 15-Jan-2013
Medication used for acute aggression in psychiatry must have rapid onset of effect, low frequency of administration and low levels of adverse effects. Zuclopenthixol acetate is said to have these properties.
- Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses
Cochrane Systematic Reviews, 20-Oct-2008
There is a clear link between stopping antipsychotic medications and a relapse of psychotic symptoms. A series of long-acting intra-muscular preparations has been developed since the 1960s in the hope of reducing the frequency of relapse and, hence, overa
